You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
李氏大藥廠(00950.HK)年度純利微增3.0%至1.29億港元 末期息3.1港仙
格隆匯 03-30 17:19

格隆匯 3 月 30日丨李氏大藥廠(00950.HK)公佈,截至2020年12月31日止年度,公司收益為12.17億港元,同比減少0.2%;毛利為7.81億港元,同比減少2.2%;公司擁有人應占溢利為1.29億港元,同比增長3.0%,基本每股盈利為21.99港仙,擬派末期息每股3.1港仙。

於報吿年度內,集團錄得收益12.17億港元,按年下跌0.2%。引進產品的銷售額為6.78億港元,佔集團收益的55.7%(2019年:56.1%),而專利及仿製產品的銷售額則為5.39億港元,佔集團收益的44.3%(2019年:43.9%)。

集團繼續加大開發新藥的研究及開發力度,2020年的研發活動開支達3.89億港元(2019年:3.26億港元),佔相應年度收入的32.0%(2019年:26.7%),相信在國內醫藥公司之間傲視同儕。當中的2.03億港元(2019年:1.50億港元)已確認為開支,而1.86億港元(2019年:1.76億港元)則資本化為無形資產。此外,於2020年,1.11億港元的引進產品許可費已確認為無形資產。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account